These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 14751501

  • 1. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.
    Mu Z, Hachem P, Agrawal S, Pollack A.
    Int J Radiat Oncol Biol Phys; 2004 Feb 01; 58(2):336-43. PubMed ID: 14751501
    [Abstract] [Full Text] [Related]

  • 2. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
    Mu Z, Hachem P, Agrawal S, Pollack A.
    Prostate; 2004 Aug 01; 60(3):187-96. PubMed ID: 15176048
    [Abstract] [Full Text] [Related]

  • 3. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.
    Stoyanova R, Hachem P, Hensley H, Khor LY, Mu Z, Hammond ME, Agrawal S, Pollack A.
    Int J Radiat Oncol Biol Phys; 2007 Jul 15; 68(4):1151-60. PubMed ID: 17637390
    [Abstract] [Full Text] [Related]

  • 4. Lack of prostate cancer radiosensitization by androgen deprivation.
    Pollack A, Salem N, Ashoori F, Hachem P, Sangha M, von Eschenbach AC, Meistrich ML.
    Int J Radiat Oncol Biol Phys; 2001 Nov 15; 51(4):1002-7. PubMed ID: 11704324
    [Abstract] [Full Text] [Related]

  • 5. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
    Mu Z, Hachem P, Hensley H, Stoyanova R, Kwon HW, Hanlon AL, Agrawal S, Pollack A.
    Prostate; 2008 May 01; 68(6):599-609. PubMed ID: 18196567
    [Abstract] [Full Text] [Related]

  • 6. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA.
    Neoplasia; 2016 Apr 01; 18(4):213-22. PubMed ID: 27108384
    [Abstract] [Full Text] [Related]

  • 7. Antisense Bcl-2 sensitizes prostate cancer cells to radiation.
    Mu Z, Hachem P, Pollack A.
    Prostate; 2005 Dec 01; 65(4):331-40. PubMed ID: 16015611
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
    Hensley HH, Hannoun-Levi JM, Hachem P, Mu Z, Stoyanova R, Khor LY, Agrawal S, Pollack A.
    Int J Cancer; 2011 Feb 15; 128(4):962-73. PubMed ID: 20960462
    [Abstract] [Full Text] [Related]

  • 10. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H, Yu D, Agrawal S, Zhang R.
    Prostate; 2003 Feb 15; 54(3):194-205. PubMed ID: 12518324
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
    Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R.
    Clin Cancer Res; 2004 Feb 15; 10(4):1263-73. PubMed ID: 14977824
    [Abstract] [Full Text] [Related]

  • 13. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line.
    Grünbaum U, Meye A, Bache M, Bartel F, Würl P, Schmidt H, Dunst J, Taubert H.
    Anticancer Res; 2001 Feb 15; 21(3B):2065-71. PubMed ID: 11497299
    [Abstract] [Full Text] [Related]

  • 14. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo.
    Udayakumar TS, Stoyanova R, Hachem P, Ahmed MM, Pollack A.
    Int J Radiat Oncol Biol Phys; 2011 Feb 01; 79(2):549-58. PubMed ID: 21195876
    [Abstract] [Full Text] [Related]

  • 15. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.
    Clin Cancer Res; 2004 Jul 15; 10(14):4858-64. PubMed ID: 15269162
    [Abstract] [Full Text] [Related]

  • 16. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z, Li M, Wang H, Agrawal S, Zhang R.
    Proc Natl Acad Sci U S A; 2003 Sep 30; 100(20):11636-41. PubMed ID: 13130078
    [Abstract] [Full Text] [Related]

  • 17. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME.
    Int J Cancer; 2001 Mar 15; 91(6):846-50. PubMed ID: 11275990
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R.
    Mol Med; 2002 Apr 15; 8(4):185-99. PubMed ID: 12149568
    [Abstract] [Full Text] [Related]

  • 19. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
    Cuellar DC, Rhee J, Kyprianou N.
    Anticancer Res; 2002 Apr 15; 22(3):1673-9. PubMed ID: 12168853
    [Abstract] [Full Text] [Related]

  • 20. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.
    Colletier PJ, Ashoori F, Cowen D, Meyn RE, Tofilon P, Meistrich ME, Pollack A.
    Int J Radiat Oncol Biol Phys; 2000 Dec 01; 48(5):1507-12. PubMed ID: 11121656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.